“There is no substitute for a mother’s milk.” – Martin H. Fischer
One of the greatest joys of a mother is being able to continue giving a baby life after you give it life. That’s the art of breastfeeding—feeding your baby life by the ounce daily.
Unfortunately, many mothers struggle with breastfeeding, as they don’t produce enough breast milk. They follow all of the rules—proper diet, plenty of water, and sleep—but still can’t create enough milk to fully supply their babies.
Moms like this should opt for the assistance of a galactagogue — a substance that’s supposed to assist in increasing milk supply. Motilium is such, and it may help with this concern.
Motilium (Domperidone) was originally introduced as a drug used to treat nausea, vomiting and other stomach problems. Though it not approved by the U.S. Food and Drug Administration (FDA), Motilium is a substance that is used to increase mother’s milk.
Here’s what breastfeeding moms need to know about Motilium.
Is Motilium Safe to Use
Motilium has a history that reaches back into the 1970’s. I was originally introduced as its base name, Domperidone, which was used to treat patients suffering from stomach disorders.
In 2004, the FDA refused to approve Motilium as a marketable drug and labeled it unsafe for breastfeeding mothers after two deaths were reported from intravenous use of the drug.
However, these intravenous uses were connected to two cancer patients who were given strong doses of Domperidone.
Motilium for breastfeeding would not be given to moms intravenously. It would be taken as an oral tablet with a controlled dose–strong enough to promote an increase in prolactin, which produces more milk.
Another notable con is that the drug could put mothers at risk of cardiac arrest.
A cardiologist in the UK touched on the idea that Domperidone stretches out the QT Interval affecting certain currents of the heart’s cells, increasing the chances of a heart attack.
Nonetheless, the risks of a heart attack from this drug are more common in people who, again, take the drug intravenously, are over the age of sixty, and are taking high oral doses of the drug daily.
When Should a Mother Consider a Galactagogue?
There are many reasons for a mother to turn to a milk enhancing substance to assist with breastfeeding.
Mothers Who Are Candidates:
- Mothers of preterm babies.
- Mothers whose prolactin levels remain in short supply.
- Mothers who have consistently low levels of breast milk.
- Women with breast implants or other breast-related surgeries.
- Women with prolonged health conditions that affect their hormones.
- Mothers of babies who don’t latch right away, slowing down the breastfeeding process.
- Women who suffer from deficient glandular tissue—undeveloped breasts that don’t have enough milk ducts.
Motilium has several side-effects—one of which is a rise in prolactin levels.
Prolactin is created by the pituitary gland, which is a tiny organ in the brand that produces different hormones in the body.
Prolactin is the hormone in a woman’s body that promotes milk production.
Since domperidone could possibly raise prolactin and act as a filler for glandular tissue, mothers who take the drug benefit from this side-effect, experiencing an increase in prolactin and a reviving of glandular tissue.
Considerably, women contemplating using the drug should first consult with their physician. A physician will examine a mother’s health thoroughly to determine if this drug or any other galactagogue is safe for her to use.
Do the Side-Effects Harm, Babies?
Unlike, Maxolon, Pramin, and Maxeran, which are all forms of Metoclopramide, domperidone has little to no side effects.
Mothers have not noted any concerns such as tiredness, stomach aches, cramping, or irregular bowel movements. Domperidone directly affects the mother’s milk supply and only traces of it gets inside of breast milk.
Babies shouldn’t experience any side effects at all. Plus, Domperidone is not a drug that mothers have to use long term.
What Is a Safe Dosage?
In a study done by the British Journal of Clinical Pharmacology, six mothers were given domperidone, ranging 30mg to 60mg daily.
Prolactin levels and milk production was monitored throughout the study.
Two-thirds of the mothers experienced an increase in milk supply at domperidone dosages of 30mg and 60mg.
At both dosages, minimum amounts of the drug were transferred into the mother’s milk, with trivial effects on the babies.
Domperidone and its generics are normally sold in doses of 10mg to be taken three to four times daily and should only be used in conjunction with any other drugs if advised by a doctor.
How Fast Does It Work?
Different studies done with different doses have reported effects of domperidone within the first ten days.
Other studies have gone on for weeks before the effects of the drug on breast milk were experienced.
Is It Addictive?
Any drug taken for a prolonged period of time could become addictive.
However, mothers have taken Domperidone with preterm infants all way through the weaning process without any problems or concerns.
That’s not to attest that the drug can be stopped cold turkey. It is, in fact, a substance that mothers should gently wean themselves away from.
Give Motilium a Try
Mother’s milk knows best. Breast milk is a lifeforce that newborn babies rely on. Every mother should be granted this experience unless otherwise declined.
But, what can a mother do if the natural process is hindered?
For many mothers, the genuine practice of breastfeeding is a struggle. Either the baby doesn’t latch on right away, her body doesn’t produce milk the way it should, or some underlying breast health issue is getting in the way.
After conventional methods have been approached, the option of galactagogues is available for mom wishing to nurse their babes until weaning age.
There are many forms of galactagogues, but one with proven minimal risks for mother and baby—Domperidone. It has been proven safe with little to no side-effects and results appear within days to a few short weeks.
Check out our blog for information on drug health and effects of certain drugs.70